Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business Context and Reporting Period
The company filed a Current Report on Form 8-K concerning its annual meeting of stockholders held on June 5, 2020. The filing was signed on June 9, 2020. Arcturus is a Delaware corporation whose common stock trades on Nasdaq under the symbol ARCT.
Of 15,156,989 shares entitled to vote, 11,692,374 shares were represented in person or by proxy, constituting a quorum.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material Changes and Stockholder Vote Results
- All seven director nominees were elected: Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Edward W. Holmes, Magda Marquet, and Karah Parschauer.
- Stockholders approved the 2020 Employee Stock Purchase Plan.
- Stockholders approved the Amended and Restated 2019 Omnibus Equity Incentive Plan, including an increase of 3,150,000 shares in the maximum number reserved for delivery under the plan.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
| Proposal | For | Against or Withhold | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Director elections | 9,092,938–9,113,491 | 53,854–74,407 | Not separately reported | 2,525,029 each |
| 2020 Employee Stock Purchase Plan | 9,156,041 | 8,703 | 2,601 | 2,525,029 |
| Amended and Restated Omnibus Plan | 8,425,865 | 736,062 | 5,418 | 2,525,029 |
| Ernst & Young ratification | 11,644,555 | 12,957 | 34,862 | N/A |
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or outlook and does not discuss specific operating risks, contingencies, or unusual accounting items.
The increase in shares reserved under the equity incentive plan may result in future equity-based compensation or dilution; the filing does not quantify the related financial impact.
Important Facts to Verify
- Review the company’s subsequent filings for the financial effects of the expanded equity incentive plan and employee stock purchase plan.
- Verify director biographies, committee assignments, and any changes in governance disclosures in subsequent proxy or periodic filings.
- Review the company’s 2020 annual and quarterly filings for revenue, cash position, liquidity runway, debt, operating losses, and research-and-development spending.
- Confirm Ernst & Young LLP’s continued appointment and any subsequent auditor changes or reportable events.